Date: 2016-05-09
Type of information: Nomination
Compound:
Company: Arsanis (USA - MA)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 9, 2016, Arsanis announced that Rene Russo has been promoted to president and chief executive officer.
Since joining Arsanis as chief development officer in August 2015, Dr. Russo spearheaded the strategy for clinical studies for Arsanis’ lead program, ASN100, aimed at the prevention and treatment of serious Staphylococcus aureus infections. Prior to Arsanis, Dr. Russo served as vice president, global medical affairs at Cubist Pharmaceuticals, with more than 10 years in increasingly senior roles within research and development at the company. She has leadership experience across all phases of drug development, including global commercial launches for five novel antibacterial agents.
In addition to Dr. Russo’s appointment to CEO, David Mantus, Ph.D., has been appointed as chief development officer. In this role he will drive strategy and planning for the continued clinical development of ASN100, along with other earlier-stage pipeline candidates. Dr. Mantus joined Arsanis in 2015, bringing more than 20 years of experience in clinical development, regulatory affairs and quality assurance, including as vice president, regulatory affairs at Cubist Pharmaceuticals.
Arsanis has also recently recruited Ed Campanaro as senior vice president, clinical operations to oversee Arsanis' global clinical trials. Prior to joining Arsanis, Mr. Campanaro served as vice president, clinical operations and data management for bluebird bio. Mr. Campanaro was also vice president, clinical development operations at Cubist Pharmaceuticals, where he oversaw complex, global clinical operations programs for a portfolio of therapies for serious infectious diseases. ASN100, is aimed at the prevention and treatment of serious Staphylococcus aureus infections and entered a Phase I clinical trial in the fall in 2015, with a Phase II study anticipated to begin in 2016.
Financial terms:
Latest news:
